LTR Pharma (ASX:LTP) executed a binding term sheet with Strive Specialties, establishing exclusive US pharmacy fulfilment rights for its intranasal erectile dysfunction treatment product ROXUS, according to a Thursday Australian bourse filing.
The term sheet provides access to a multi-state 503A pharmacy platform to support national pharmacy fulfilment.
The agreement has a two-year initial term from commercial launch, with annual autorenewal unless either party elects not to renew. The product will be supplied through a multi-channel strategy incorporating telehealth, pharmacy fulfilment, and healthcare provider networks.
Its shares soared 22% in recent trading on Thursday.